Replies to post #57440 on Avid Bioservices Inc (CDMO)

[jonnyrocket]

CJ - thanks for all of the updated DD you continue to provide...great job as always.

[sunstar]

Stunning indeed; Cotara overwhelms Temodar, Standard of Care for glioblastoma multiforme, (GBM) by a factor of 3.58 times mean overall survival time.

This morning’s Reuters coverage sharply picked up on that ability of Cotara to exceed Temodar’s 24 weeks by 3.58 times extending survival to 86 weeks. That is off the charts and amazingly good news for sufferers of deadly glioblastoma multiforme.

Cotara has also delivered some particularly long term survival by factors of many years for some patients; all this, not in first line, but in recurrent high grade gliomas.

With Orphan Drug Status and Fast Track Designation, it looks like Cotara data sets it up to move ahead to be the next Standard of Care; a winner for glio patients and for Peregrine as well.

sunstar